CoreStock

Stock price

Track all markets on TradingView

Market cap

At each fiscal year end, then the latest quarter end: closing price × shares outstanding.

Show table
Vertex Pharmaceuticals market cap, annual
PeriodMarket cap
FY2016, ended Dec 31, 2016$18.3B
FY2017, ended Dec 31, 2017$38.0B
FY2018, ended Dec 31, 2018$42.4B
FY2019, ended Dec 31, 2019$56.8B
FY2020, ended Dec 31, 2020$61.4B
FY2021, ended Dec 31, 2021$55.9B
FY2022, ended Dec 31, 2022$74.2B
FY2023, ended Dec 31, 2023$105B
FY2024, ended Dec 31, 2024$103B
FY2025, ended Dec 31, 2025$115B
Trailing 12 months to Jun 30, 2026 (through Q2 FY2026)$126B

Revenue

By fiscal year, then the trailing 12 months

Show table
Vertex Pharmaceuticals revenue, annual
PeriodRevenue
FY2016, ended Dec 31, 2016$1.70B
FY2017, ended Dec 31, 2017$2.49B
FY2018, ended Dec 31, 2018$3.05B
FY2019, ended Dec 31, 2019$4.16B
FY2020, ended Dec 31, 2020$6.21B
FY2021, ended Dec 31, 2021$7.57B
FY2022, ended Dec 31, 2022$8.93B
FY2023, ended Dec 31, 2023$9.87B
FY2024, ended Dec 31, 2024$11.0B
FY2025, ended Dec 31, 2025$12.0B
Trailing 12 months to Jun 30, 2026 (through Q2 FY2026)$12.6B

Net income and free cash flow

By fiscal year, then the trailing 12 months. Free cash flow is operating cash flow minus capex.

Show table
Vertex Pharmaceuticals net income and free cash flow, annual
PeriodNet incomeFree cash flow
FY2016, ended Dec 31, 2016−$112M$180M
FY2017, ended Dec 31, 2017$263M$746M
FY2018, ended Dec 31, 2018$2.10B$1.17B
FY2019, ended Dec 31, 2019$1.18B$1.49B
FY2020, ended Dec 31, 2020$2.71B$2.99B
FY2021, ended Dec 31, 2021$2.34B$2.41B
FY2022, ended Dec 31, 2022$3.32B$3.93B
FY2023, ended Dec 31, 2023$3.62B$3.34B
FY2024, ended Dec 31, 2024−$536M−$790M
FY2025, ended Dec 31, 2025$3.95B$3.19B
Trailing 12 months to Jun 30, 2026 (through Q2 FY2026)$4.41B$3.80B

Cash and cash equivalents

At each fiscal year end, then the latest quarter end.

Show table
Vertex Pharmaceuticals cash and cash equivalents, annual
PeriodCash and cash equivalents
FY2016, ended Dec 31, 2016$1.18B
FY2017, ended Dec 31, 2017$1.67B
FY2018, ended Dec 31, 2018$2.65B
FY2019, ended Dec 31, 2019$3.11B
FY2020, ended Dec 31, 2020$5.99B
FY2021, ended Dec 31, 2021$6.79B
FY2022, ended Dec 31, 2022$10.5B
FY2023, ended Dec 31, 2023$10.4B
FY2024, ended Dec 31, 2024$4.57B
FY2025, ended Dec 31, 2025$5.08B
Trailing 12 months to Jun 30, 2026 (through Q2 FY2026)$6.14B

Total debt

At each fiscal year end, then the latest quarter end. Short- and long-term borrowings, excluding leases.

No figures for this period in the company’s filings.

Shares outstanding

At each fiscal year end, then the latest quarter end, adjusted for splits. Up 2.0% since FY16.

Show table
Vertex Pharmaceuticals shares outstanding, annual
PeriodShares outstanding
FY2016, ended Dec 31, 2016248M
FY2017, ended Dec 31, 2017254M
FY2018, ended Dec 31, 2018256M
FY2019, ended Dec 31, 2019259M
FY2020, ended Dec 31, 2020260M
FY2021, ended Dec 31, 2021255M
FY2022, ended Dec 31, 2022257M
FY2023, ended Dec 31, 2023258M
FY2024, ended Dec 31, 2024257M
FY2025, ended Dec 31, 2025254M
Trailing 12 months to Jun 30, 2026 (through Q2 FY2026)253M

Buybacks and new shares

By fiscal year, then the trailing 12 months, in dollars. Below zero: bought back. Above zero: issued to employees, sold or used in acquisitions.

Show table
Vertex Pharmaceuticals share buybacks and issuance, annual
PeriodBought backPaid to employees
FY2016, ended Dec 31, 2016$0$241M
FY2017, ended Dec 31, 2017$0$293M
FY2018, ended Dec 31, 2018$350M$325M
FY2019, ended Dec 31, 2019$186M$361M
FY2020, ended Dec 31, 2020$539M$430M
FY2021, ended Dec 31, 2021$1.43B$441M
FY2022, ended Dec 31, 2022$0$491M
FY2023, ended Dec 31, 2023$428M$581M
FY2024, ended Dec 31, 2024$1.18B$699M
FY2025, ended Dec 31, 2025$2.02B$686M
Trailing 12 months to Jun 30, 2026 (through Q2 FY2026)$2.01B$689M